Skip to main content
  • SGLT2i ‘Well Tolerated’ With Favorable Outcomes in Previously Untested ATTR-CM Patients – Observational Study

    Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were well tolerated and showed “favorable” outcomes for transthyretin cardiomyopathy (ATTR-CM) patients in a new U.S./European observational study.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details